Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia
Study sponsor: Spruce Biosciences
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2019-07-08Actual
Enrollment · participants11Actual
Source updated2025-04-01Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.